Molecular phenotyping of a UK population: defining the human serum metabolome

Metabolomics

Volumn 11, Issue 1, 2015, Pages 9-26

  Dunn, Warwick B ^a,b,c   Lin, Wanchang ^a,b   Broadhurst, David ^a,d   Begley, Paul ^a,b   Brown, Marie ^a,b   Zelena, Eva ^a   Vaughan, Andrew A ^a   Halsall, Antony ^a   Harding, Nadine ^a   Knowles, Joshua D ^a   Francis McIntyre, Sue ^a   Tseng, Andy ^a   Ellis, David I ^a   O’Hagan, Steve ^a   Aarons, Gill ^a   Benjamin, Boben ^a   Chew Graham, Stephen ^a   Moseley, Carly ^a   Potter, Paula ^a   Winder, Catherine L ^a   Potts, Catherine ^a   Thornton, Paula ^a   McWhirter, Catriona ^a   Zubair, Mohammed ^a   Pan, Martin ^e   Burns, Alistair ^a   Cruickshank, J Kennedy ^a,f   Jayson, Gordon C ^a   Purandare, Nitin ^a   Wu, Frederick C W ^a   Finn, Joe D ^a   Haselden, John N ^e   Nicholls, Andrew W ^e   Wilson, Ian D ^g,h   Goodacre, Royston ^a   Kell, Douglas B ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e GLAXOSMITHKLINE   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Clinical biochemistry; Human serum; Mass spectrometry; Metabolic phenotyping; UK population

Indexed keywords

EID: 84939874709     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0707-1     Document Type: Article

References (69)

1. Bachi, A., Dalle-Donne, I., & Scaloni, A. (2013). Redox proteomics: Chemical principles, methodological approaches and biological/biomedical promises. Chemical Reviews,113, 596–698. doi:10.1021/cr300073p.
2. Bathe, O. F., et al. (2011). Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiology, Biomarkers and Prevention,20, 140–147. doi:10.1158/1055-9965.EPI-10-0712.
3. Begley, P., et al. (2009). Development and performance of a gas chromatography–time-of-flight mass spectrometry analysis for large-scale non-targeted metabolomic studies of human serum. Analytical Chemistry,81, 7038–7046.
4. Bouatra, S., et al. (2013). The human urine metabolome. PLoS One,8, e73076. doi:10.1371/journal.pone.0073076.
5. Breiman, L. (2001). Random forests. Machine Learning,45, 5–32.
6. Broadhurst, D., & Kell, D. B. (2006). Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics,2, 171–196. doi:10.1007/s11306-006-0037-z.
7. Brown, M., et al. (2009). Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst,134, 1322–1332.
8. Brown, M., et al. (2011). Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics,27, 1108–1112. doi:10.1093/bioinformatics/btr079.
9. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature,414, 813–820. doi:10.1038/414813a.
10. Button, K. S., et al. (2013). Power failure: Why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience,14, 365–376. doi:10.1038/nrn3475.
11. Camacho, D., de la Fuente, A., & Mendes, P. (2005). The origins of correlations in metabolomics data. Metabolomics,1, 53–63.
12. Cheng, S. S., et al. (2012). Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation,125, 2222–2231. doi:10.1161/Circulationaha.111.067827.
13. Cho, J. H., Lee, D., Park, J. H., & Lee, I. B. (2004). Gene selection and classification from microarray data using kernel machine. FEBS Letters,571, 93–98. doi:10.1016/j.febslet.2004.05.087.
14. Cristianini, N., & Shawe-Taylor, J. (2000). An introduction to support vector machines and other kernel-based learning methods. Cambridge: Cambridge University Press.
15. Delpierre, G., & Van Schaftingen, E. (2003). Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochemical Society Transactions,31, 1354–1357.
16. Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., & Griffin, J. L. (2011a). Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews,40, 387–426.
17. Dunn, W. B., Wilson, I. D., Nicholls, A. W., & Broadhurst, D. (2012). The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis,4, 2249–2264. doi:10.4155/bio.12.204.
18. Dunn, W. B., et al. (2011b). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols,6, 1060–1083.
19. Dwork, C., Kumar, R., Naor, M., Sivakumar, D. (2001). Rank aggregation methods for the Web. In Proceedings of the 10th International World Wide Web Conference (pp. 613–622).
20. Efron, B., & Tibshirani, R. J. (1993). Introduction to the bootstrap. London: Chapman and Hall.
21. Friend, A., Craig, L., & Turner, S. (2013). The prevalence of metabolic syndrome in children: A systematic review of the literature. Metabolic Syndrome and Related Disorders,11, 71–80. doi:10.1089/met.2012.0122.
22. Gavaghan, C. L., Holmes, E., Lenz, E., Wilson, I. D., & Nicholson, J. K. (2000). An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: Application to the C57BL10J and Alpk: ApfCD mouse. FEBS Letters,484, 169–174.
23. Goodacre, R., et al. (2007). Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics,3, 231–241.
24. Haug, K., et al. (2013). MetaboLights-an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Research,41, D781–D786. doi:10.1093/Nar/Gks1004.
25. He, J., & Whelton, P. K. (1999). Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials. American Heart Journal,138, 211–219.
26. Holmes, E., et al. (2008). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature,453, 396–400. doi:10.1038/nature06882.
27. Ioannidis, J. P. A. (2005). Why most published research findings are false. PLoS Medicine,2, e124.
28. Ioannidis, J. P. A., & Panagiotou, O. A. (2011). Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA,305, 2200–2210.
29. Kell, D. B. (2004). Metabolomics and systems biology: Making sense of the soup. Current Opinion in Microbiology,7, 296–307.
30. Kell, D. B. (2006a). Metabolomics, modelling and machine learning in systems biology: Towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. FEBS Journal,273, 873–894.
31. Kell, D. B. (2006b). Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discovery Today,11, 1085–1092.
32. Kell, D. B. (2009). Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics,2, 2.
33. Kell, D. B. (2013). Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: Where drug discovery went wrong and how to fix it. FEBS Journal,280, 5957–5980.
34. Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2013). The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: What we (need to) know and how we can do so. Drug Discovery Today,18, 218–239.
35. Kell, D. B., & Goodacre, R. (2014). Metabolomics and systems pharmacology: Why and how to model the human metabolic network for drug discovery. Drug Discovery Today,19, 171–182.
36. Kell, D. B., & Oliver, S. G. (2004). Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. BioEssays,26, 99–105.
37. Kell, D. B., & Westerhoff, H. V. (1986). Metabolic control theory: Its role in microbiology and biotechnology. FEMS Microbiology Reviews,39, 305–320.
38. Kochhar, S., Jacobs, D. M., Ramadan, Z., Berruex, F., Fuerholz, A., & Fay, L. B. (2006). Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Analytical Biochemistry,352, 274–281. doi:10.1016/j.ab.2006.02.033.
39. Kopka, J., et al. (2005). GMD@CSB.DB: The Golm metabolome database. Bioinformatics,21, 1635–1638.
40. Kotze, H. L., et al. (2013). A novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions. BMC Systems Biology,7, 107. doi:10.1186/1752-0509-7-107.
41. Lawton, K. A., et al. (2008). Analysis of the adult human plasma metabolome. Pharmacogenomics,9, 383–397. doi:10.2217/14622416.9.4.383.
42. Lee, D. M., et al. (2009). Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. European Journal of Endocrinology,161, 947–954. doi:10.1530/EJE-09-0496.
43. Liebich, H. M., & Pickert, A. (1985). Gas chromatographic profiling of phenolic acids in urine of patients with cirrhosis of the liver. Journal of Chromatography,338, 25–32.
44. Lu, L., et al. (2009). Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care,32, 1278–1283. doi:10.2337/Dc09-0209.
45. Mao, Y. Y., et al. (2008). A pilot study of GC/MS-based serum metabolic profiling of acute rejection in renal transplantation. Transplant Immunology,19, 74–80. doi:10.1016/j.trim.2008.01.006.
46. Menni, C., et al. (2013). Metabolomic markers reveal novel pathways of ageing and early development in human populations. International Journal of Epidemiology,42, 1111–1119. doi:10.1093/ije/dyt094.
47. Newgard, C. B., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism,9, 311–326. doi:10.1016/j.cmet.2009.02.002.
48. Nicholson, J. K., Everett, J. R., & Lindon, J. C. (2012). Longitudinal pharmacometabonomics for predicting patient responses to therapy: Drug metabolism, toxicity and efficacy. Expert Opinion on Drug Metabolism & Toxicology,8, 135–139. doi:10.1517/17425255.2012.646987.
49. Nicholson, G., et al. (2011). Human metabolic profiles are stably controlled by genetic and environmental variation. Molecular Systems Biology,7, 525.
50. Pradhan, A. (2007). Obesity, metabolic syndrome, and type 2 diabetes: Inflammatory basis of glucose metabolic disorders. Nutrition Reviews,65, S152–S156.
51. Psychogios, N., et al. (2011). The human serum metabolome. PLoS One,6, e16957. doi:10.1371/journal.pone.0016957.
52. Raamsdonk, L. M., et al. (2001). A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotechnology,19, 45–50.
53. Rupérez, F. J., et al. (2012). Metabolomic study of plasma of patients with abdominal aortic aneurysm. Analytical and Bioanalytical Chemistry,403, 1651–1660. doi:10.1007/s00216-012-5982-y.
54. Sealey, W. M., Teague, A. M., Stratton, S. L., & Mock, D. M. (2004). Smoking accelerates biotin catabolism in women. American Journal of Clinical Nutrition,80, 932–935.
55. Slupsky, C. M., et al. (2007). Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Analytical Chemistry,79, 6995–7004. doi:10.1021/ac0708588.
56. Suhre, K., & Gieger, C. (2012). Genetic variation in metabolic phenotypes: Study designs and applications. Nature Reviews Genetics,13, 759–769. doi:10.1038/Nrg3314.
57. Suhre, K., et al. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature,477, 54–60.
58. Sumner, L. W., et al. (2007). Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics,3, 211–221. doi:10.1007/s11306-007-0082-2.
59. Swainston, N., Mendes, P., & Kell, D. B. (2013). An analysis of a ‘community-driven’ reconstruction of the human metabolic network. Metabolomics,9, 757–764.
60. Thiele, I., et al. (2013). A community-driven global reconstruction of human metabolism. Nature Biotechnology,31, 419–425.
61. van der Greef, J., Hankemeier, T., & McBurney, R. N. (2006). Metabolomics-based systems biology and personalized medicine: Moving towards n = 1 clinical trials? Pharmacogenomics,7, 1087–1094.
62. Vidal, M., Cusick, M. E., & Barabási, A. L. (2011). Interactome networks and human disease. Cell,144, 986–998.
63. Wang, J., & Li, M. D. (2010). Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology,35, 702–719. doi:10.1038/npp.2009.178.
64. Wang, T. J., et al. (2011). Metabolite profiles and the risk of developing diabetes. Nature Medicine,17, 448–453.
65. Wold, S., Sjöström, M., & Eriksson, L. (2001). PLS-regression: A basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems,58, 109–130. doi:10.1016/S0169-7439(01)00155-1.
66. Xia, J. G., Broadhurst, D. I., Wilson, M., & Wishart, D. S. (2013). Translational biomarker discovery in clinical metabolomics: An introductory tutorial. Metabolomics,9, 280–299. doi:10.1007/s11306-012-0482-9.
67. Yap, I. K. S., et al. (2010). Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. Journal of Proteome Research,9, 6647–6654. doi:10.1021/pr100798r.
68. Yu, Z. H., et al. (2012). Human serum metabolic profiles are age dependent. Aging Cell,11, 960–967. doi:10.1111/j.1474-9726.2012.00865.x.
69. Zelena, E., et al. (2009). Development of a robust and repeatable UPLC–MS method for the long-term metabolomic study of human serum. Analytical Chemistry,81, 1357–1364.